Search results for "vaccines"

Article EMA Invites Comments on New Guidance for Vaccine Development
The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of…

Article EMA Guidance on Changes to COVID-19 Vaccines to Fight Variants
The European Medicines Agency (EMA) has requested that developers determine if their COVID-19 vaccines protect against new virus mutations that have been identified in the United Kingdom, South Africa…

Poster Biacore™ systems in vaccine development and production
The growing public awareness of a potential pandemic requiring rapid treatment of millions of healthy individuals has spurred renewed interest in vaccines. Vaccination campaigns mean that often very…

Article Flavivirus Vaccine: Accelerate Development and Production with Modern Tools and Solutions
The complex nature of flaviviruses makes process development technically challenging. In addition, vaccine production can be both costly and difficult to scale to meet market demands. This article giv…

Article Manufacturing of Vaccines and Viral Vectors
Click here to read the article >>  With the pandemic outbreak of COVID-19, there is intense focus on developing a vaccine. However, the challenge not only lies in developing a vaccine but also i…

Article Accelerated flavivirus vaccine production with modern tools and solutions
Flavivirus vaccine development and production constitute many challenges and can be both space-and resource-consuming. This white paper gives an overview of modern tools and solutions, adding flexib…

Poster Development of a chemically defined medium for virus vaccine production in a duck suspension cell line
A project was initiated to improve the production process for viral vaccines through the use of the EB66® cell line derived from duck embryonic stem cells and proprietary to Valneva. The primary goa…

Poster Residual DNA analysis in influenza vaccine processing
In cell-based influenza vaccine production, the European Pharmacopoeia demands a host cell residual DNA concentration of less than 10 ng per dose. To reliably measure residual DNA in both process sa…

Article Diamyd Medical Selects Cytiva’s FlexFactory Platform to Make Precision Medicine Type-1 Diabetes Vaccine
Click here to learn more >> Diamyd Medical will install a new Cytiva FlexFactory platform in Umeå, Sweden. Once up and running, the clinical-stage biopharmaceutical company will begin manufactu…

Article Faster Flavivirus Vaccine Production
Viral vaccines need to be produced fast and in large quantities. Routine immunizations and preventive campaigns, like stockpiling in response to emergencies, involve millions of doses, and speed is es…

Previous PageNext Page